NCLEX Review Guide: Monoclonal Antibody Therapy for Respiratory Conditions

Mechanism of Action

• Monoclonal antibodies are laboratory-produced molecules engineered to bind to specific targets in the immune system. They work by blocking inflammatory pathways that contribute to respiratory conditions like asthma and COPD.
• These medications target specific cytokines, immunoglobulins, or cell surface receptors to reduce airway inflammation and prevent bronchoconstriction.

Anti-IgE Therapy

• Omalizumab (Xolair) binds to IgE antibodies, preventing them from triggering allergic asthma responses. Used for moderate to severe persistent allergic asthma in patients ≥6 years old.
• Administered every 2-4 weeks via subcutaneous injection, with dosing based on baseline IgE levels and body weight.

Anti-IL5 Therapy

• Mepolizumab (Nucala) and Reslizumab (Cinqair) target interleukin-5, reducing eosinophil production and activation in severe eosinophilic asthma.
• Benralizumab (Fasenra) blocks the IL-5 receptor, causing rapid depletion of eosinophils and basophils.

Pre-Administration Assessment

1. Verify appropriate candidate: severe, uncontrolled asthma despite optimal therapy
2. Review baseline laboratory values (CBC, eosinophil count, total IgE if applicable)
3. Assess for active infections or immunocompromised state
4. Obtain informed consent and educate about risks/benefits

Administration Guidelines

• Rotate injection sites for subcutaneous medications to prevent lipodystrophy and ensure consistent absorption.
• Allow refrigerated medications to reach room temperature before injection to reduce discomfort and improve patient tolerance.

Essential Patient Teaching

• Explain that monoclonal antibodies are add-on therapy, not replacements for rescue inhalers or controller medications.
• Emphasize the importance of continuing prescribed asthma medications even when feeling better, as biologics work alongside existing treatments.
• Teach patients to report signs of infection immediately, as these medications can suppress immune function.

Ongoing Monitoring

• Track asthma control measures: frequency of rescue inhaler use, nighttime awakenings, and exacerbation rates.
• Monitor for parasitic infections, especially in patients with travel history to endemic areas, as eosinophil suppression increases risk.

Self-Assessment Checklist

• ☐ Can identify monoclonal antibodies by "-mab" suffix
• ☐ Understand these are add-on, not replacement therapies
• ☐ Know anaphylaxis monitoring requirements
• ☐ Can differentiate between anti-IgE and anti-IL5 mechanisms
• ☐ Understand patient selection criteria for biologic therapy